Innoviva (INVA) Misses Q3 EPS by 5c

Innoviva (NASDAQ: INVA) reported Q3 EPS of $0.14, $0.05 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $33.3 million versus the consensus estimate of $37.74 million.

For earnings history and earnings-related data on Innoviva (INVA) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance